Results 1 to 10 of about 192 (126)

DFMO inhibition of neuroblastoma tumorigenesis

Cancer Medicine
Background Most high‐risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event‐free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during ...
David Foureau, Giselle Saulnier Sholler
exaly   +4 more sources

Difluoromethylornithine (DFMO) and AMXT 1501 inhibit capsule biosynthesis in pneumococci

Scientific Reports, 2022
Polyamines are small cationic molecules that have been linked to various cellular processes including replication, translation, stress response and recently, capsule regulation in Streptococcus pneumoniae (Spn, pneumococcus).
Moses B. Ayoola, Leslie A. Shack, Jung Hwa Lee, Juhyeon Lim, Hyungjin Eoh, Edwin Swiatlo, Otto Phanstiel, Bindu Nanduri   +7 more
doaj   +3 more sources

Maintenance DFMO Increases Survival in High Risk Neuroblastoma [PDF]

Scientific Reports, 2018
AbstractHigh risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half of patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance therapy to prevent ...
Peter Zage, William Ferguson, Kathleen A Neville   +2 more
exaly   +5 more sources

Thymoquinone and Difluoromethylornithine (DFMO) Synergistically Induce Apoptosis of Human Acute T Lymphoblastic Leukemia Jurkat Cells Through the Modulation of Epigenetic Pathways

Technology in Cancer Research and Treatment, 2020
Thymoquinone (TQ), a natural anticancer agent exerts cytotoxic effects on several tumors by targeting multiple pathways, including apoptosis. Difluoromethylornithine (DFMO), an irreversible inhibitor of the ornithine decarboxylase (ODC) enzyme, has shown
Syed Razvi, Mazin Zamzami, Hani Choudhry   +2 more
exaly   +2 more sources

Polyamine Inhibition with DFMO: Shifting the Paradigm in Neuroblastoma Therapy

Journal of Clinical Medicine
Neuroblastoma is a common childhood malignancy, and high-risk presentations, including an MYCN amplified status, continue to result in poor survival. Difluoromethylornithine (DFMO) is a new and well-tolerated treatment for high-risk neuroblastoma. This review article discusses preclinical and clinical data that resulted in the establishment of DFMO as ...
Joseph W Schramm
exaly   +3 more sources

Use of Eflornithine (DFMO) in the Treatment of Early Alzheimer's Disease: A Compassionate Use, Single-Case Study

Frontiers in Aging Neuroscience, 2018
Background: Recent genome-wide association screening (GWAS) studies have linked Alzheimer's disease (AD) neuropathology to gene networks that regulate immune function. Kan et al.
Jessica Alber, Peter Snyder, Kelly A McGarry   +2 more
exaly   +3 more sources

Difluoromethylornithine (DFMO) and Neuroblastoma: A Review

Cureus, 2023
Neuroblastoma is a type of cancer that affects the sympathetic nervous system and is the most common extracranial solid tumor in children. Difluoromethylornithine (DFMO) is a drug that has shown promise as a treatment option for high-risk neuroblastoma.
Tangella, Adarsh Vardhan, Gajre, Ashwin S, Chirumamilla, Punith Chowdary, Rathhan, Pemma V   +3 more
openaire   +2 more sources

Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis

Frontiers in Oncology, 2023
ObjectivesTo evaluate the efficacy of Difluoromethylornithine (DFMO) chemoprevention in the high-risk population for colorectal cancer (CRC).MethodsMeta-analysis was conducted to assess the caliber of the included literature by searching five databases ...
Lifeng Yang, Yan Wang, Shasha Hu, Xiaoyan Wang   +3 more
doaj   +1 more source

The First Insight Into the Supramolecular System of D,L-α-Difluoromethylornithine: A New Antiviral Perspective

Frontiers in Chemistry, 2021
Targeting the polyamine biosynthetic pathway by inhibiting ornithine decarboxylase (ODC) is a powerful approach in the fight against diverse viruses, including SARS-CoV-2.
Joanna Bojarska, Roger New, Paweł Borowiecki, Milan Remko, Martin Breza, Izabela D. Madura, Andrzej Fruziński, Anna Pietrzak, Wojciech M. Wolf   +8 more
doaj   +1 more source

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. [PDF]

PLoS ONE, 2015
Neuroblastoma (NB) is the most common cancer in infancy and most frequent cause of death from extracranial solid tumors in children. Ornithine decarboxylase (ODC) expression is an independent indicator of poor prognosis in NB patients.
Giselle L Saulnier Sholler, Eugene W Gerner, Genevieve Bergendahl, Robert B MacArthur, Alyssa VanderWerff, Takamaru Ashikaga, Jeffrey P Bond, William Ferguson, William Roberts, Randal K Wada, Don Eslin, Jacqueline M Kraveka, Joel Kaplan, Deanna Mitchell, Nehal S Parikh, Kathleen Neville, Leonard Sender, Timothy Higgins, Masao Kawakita, Kyoko Hiramatsu, Shun-Suke Moriya, André S Bachmann   +21 more
doaj   +1 more source